An update from Cizzle Biotechnology Holdings PLC ( (GB:CIZ) ) is now available.
Cizzle Biotechnology Holdings PLC has appointed Matt Bower as a Non-Executive Director, enhancing its strategic and business capabilities. Bower’s experience in strategic advisory roles and his previous involvement with Cizzle will aid the company as it prepares to launch its lung cancer test in North America and the Caribbean, marking a significant growth phase.
More about Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings PLC is a UK-based diagnostics company focused on developing early cancer detection tests. The company has pioneered a non-invasive, cost-effective blood test for early-stage lung cancer detection using the CIZ1B biomarker, and it has established commercial royalty-bearing licensing agreements and collaborations with cancer care centers. Cizzle was listed on the London Stock Exchange in May 2021.
YTD Price Performance: 6.45%
Average Trading Volume: 1,186,151
Technical Sentiment Signal: Buy
Current Market Cap: £6.54M
Learn more about CIZ stock on TipRanks’ Stock Analysis page.